Review: Point-of-Care Biomarker May Help Cut Antibiotic Use

This article originally appeared here.
Share this content:
Review: Point-of-Care Biomarker May Help Cut Antibiotic Use
Review: Point-of-Care Biomarker May Help Cut Antibiotic Use

(HealthDay News) -- The point-of-care C-reactive protein biomarker test of infection can reduce antibiotic use, although it does not affect clinical recovery, according to a review published online Nov. 6 in The Cochrane Library.

Rune Aabenhus, M.D., from the University of Copenhagen in Denmark, and colleagues examined the benefits and harms of point-of-care biomarker tests of infection for guiding antibiotic treatment in patients presenting with symptoms of acute respiratory infections. Data were reviewed from six trials (three randomized controlled trials [RCTs] and three cluster-RCTs) involving 3,284 participants that assessed the only point-of-care biomarker of infection, C-reactive protein.

The researchers observed a reduction in the use of antibiotic treatments in the C-reactive protein versus the standard-of-care group. The pooled risk ratio was 0.78 (95 percent confidence interval, 0.66 to 0.92; I², 68 percent); however, due to a high level of heterogeneity and statistically significant test for subgroup differences between the RCTs and cluster-RCTs, the results of the meta-analysis should be interpreted with caution. There was no difference in clinical recovery for use of the C-reactive protein point-of-care test and standard care. One study showed an increase in hospitalizations in the C-reactive protein group.

"A more precise effect estimate is needed to assess the costs of the intervention and compare the use of a point-of-care biomarker to other antibiotic-saving strategies," the authors write.

One author disclosed financial ties to Brahms Diagnostica (now Thermo-Fischer).

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA OKs Doptelet for Liver Dz Patients Undergoing Procedures

FDA OKs Doptelet for Liver Dz Patients Undergoing ...

Doptelet reduces the need for platelet transfusion or any rescue therapy on day of procedure

Slower Decline in Lung Function With Anthocyanin Intake

Slower Decline in Lung Function With Anthocyanin Intake

Slower annual rates of decline in FEV1 and FVC for those in highest quartile of anthocyanin intake

Bioengineering Feasible for Airway Reconstruction

Bioengineering Feasible for Airway Reconstruction

Bioengineered tracheal and bronchial reconstruction reported using stented aortic matrices

is free, fast, and customized just for you!

Already a member?

Sign In Now »